Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus SYLATRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus SYLATRON.
ADEFOVIR DIPIVOXIL vs SYLATRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Peginterferon alfa-2b binds to type I interferon receptors, activating JAK-STAT signaling and inducing expression of antiviral, antiproliferative, and immunomodulatory proteins.
10 mg orally once daily on an empty stomach.
200 mcg/kg subcutaneously once weekly for 1 year in combination with oral ribavirin.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Terminal elimination half-life is approximately 40 hours (range 27-60 hours) following subcutaneous administration. This prolonged half-life supports once-weekly dosing.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Renal clearance is the primary route of elimination for peginterferon alfa-2b. Approximately 30% of the dose is excreted unchanged in urine, with the remainder metabolized and excreted via bile/feces.
Category C
Category C
Antiviral
Interferon Antineoplastic/Antiviral